{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Subjects in CR D100 and D180"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Subjects in sCR D100 and 180"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Subjects in VGPR D100 and D180"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Subjects in PR D100 and D180"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Subjects with SD at D+100 and 180"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Subjects with improved response at D100 and D180"},{"measurements":[{"groupId":"OG000","value":"4"}],"title":"Subjects with poorer response at D100 and D180"},{"measurements":[{"groupId":"OG000","value":"2"}],"title":"Subjects with no disease response reported"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"To determine whether lenalidomide maintenance plus the late booster immunizations leads to improved myeloma clinical responses between day 180 and day 100 post-transplant.","groups":[{"description":"All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0.","id":"OG000","title":"Prevnar, T Cells, Lenalidomide, MAGE A-3"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Subjects that reached D100 and D180","reportingStatus":"POSTED","timeFrame":"Between day 100 and 180 post transplant","title":"Primary Myeloma Endpoint","type":"PRIMARY","unitOfMeasure":"Participants"}